Menu
Health equity is defined as everyone having a fair and just opportunity to be as healthy as possible, an ethical and human rights principle that motivates us to eliminate health disparities. From building trusting relationships between patients and their healthcare providers, to dismantling racism that Black, Indigenous, and People of Color (BIPOC) patients and healthcare providers encounter, to overcoming the perceived lack of trustworthiness of healthcare systems, the barriers to achieving equity are high.
This 3-part, monthly webinar series focuses on building the skills and knowledge base necessary to generate and sustain trust, to reduce or remove these barriers and achieve equitable health outcomes for everyone.
Clinical Professor of Medicine and Medical Oncology
Department of Medical Oncology Director, Center to Eliminate Cancer Disparities
Associate Director, Diversity Affairs
Sidney Kimmel Cancer Center at Jefferson
116th President National Medical Association
Brigadier General (Ret.) United States Air Force
Philadelphia, Pennsylvania
Director and Lipman Chair in Oncology
VCU Massey Cancer Center
Richmond, Virginia
Broadcast July 12, 2023
Racial differences in clinical trial participation and therapeutic outcomes
Michigan State University |
Lansing, Michigan
Unequal outcomes for Black women, what is the role of trust in eliminating disparities?
Rethinking risk, screening and treatment for Black patients
Weill Cornell Medicine |
New York, New York
Levine Cancer Institute l Charlotte, North Carolina
Broadcast May 30, 2023
Slides were not approved for release.
Miami Cancer Institute |
Miami, Florida
The target audience for this activity is community and academic medical oncologists, advanced practitioners (NP/PA/PharmD), and other healthcare providers who treat patients in the communities that are affected by inequity in the health care system, lack trust in the health care system, and treat patients with diseases and conditions that have less than optimal outcomes as a result of inequity and distrust. Physicians in the hematology and oncology space are a primary but not exclusive target audience.
After participating in the activity, participants should be better able to:
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity. These relationships have been mitigated:
Manmeet Ahluwalia, MD, MBA, FASCO
Employee/Owner: Miami Cancer Institute at Baptist Health South Florida
Grants/Research Support: Seagen
Consultant/Advisory Board: Bayer, Novocure, Kiyatec, Insightec, GSK, Xoft, Nuvation, Cellularity, SDP Oncology, Apollomics, Prelude, Janssen, Tocagen, Voyager Therapeutics, Viewray, Canis Lifesciences, Pyramid Biosciences, Varian Medical Systems, Cairn Therapeutics, Anheart Therapeutics, Theraguix, Menarini Ricerche, Modifi biosciences., Bugworks
Non-Mutual funds/Stock Ownership/Stock Options: Mimivax, Cytodyn, Medlnnovate Advisors LLC
Craig Emmitt Cole, MD
Discussion Board/Consultation: AbbVie, AstraZeneca, Genentech Research, GSK, Janssen, Pfizer, Sanofi
Edith Mitchell, MD, MACP, FCPP, FRCP (London)
Employee/Owner: Sidney Kimmel Cancer Center at Jefferson (Employee)
Grants/Research Support: Amgen, Bristol Myers Squibb, Genentech, Sanofi (Grant support to the institution)
Speakers’ Bureau/Honoraria for non-CME: Genentech, Ipsen
Consultant/Advisory Board: Amgen, Astellas, Bristol Myers Squibb, Genentech, Taiho
Laura Musselwhite, MD, MPH
Advisory Board: AstraZeneca
Consultant: AlphaSights, First Thought
Lisa Newman, MD, MPH, FACS, FASCO, FSSO
No relevant financial relationships to disclose
Robert Winn, MD
Employee/Owner: Founding Member: Robert A. Winn Diversity in Clinical Trials Award Program established by the Bristol Myers Squibb Foundation
Grants/Research Support: Stand Up to Cancer, Merck
Consultant/Advisory Board: LUNGevity Foundation, American Cancer Society, Genentech, Phillips
The PIM planners and others have nothing to disclose. The Bio Ascend planners and others have nothing to disclose.
In order to obtain your CE certificate, please follow the steps below at the conclusion of the activity:
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better (if applicable) and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.
This activity is supported by independent educational grants from Genentech, a member of the Roche Group., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
We use cookies for various purposes including enabling website functionality and targeted marketing activities. For more information about cookies, please review our Privacy & Cookie Notice.